These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 22765255)
1. Estimating preference-based EQ-5D health state utilities or item responses from neuropathic pain scores. Gu NY; Bell C; Botteman MF; Ji X; Carter JA; van Hout B Patient; 2012; 5(3):185-97. PubMed ID: 22765255 [TBL] [Abstract][Full Text] [Related]
2. Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease. Moore A; Young CA; Hughes DA Value Health; 2018 Nov; 21(11):1322-1329. PubMed ID: 30442280 [TBL] [Abstract][Full Text] [Related]
3. Mapping of the Insomnia Severity Index and other sleep measures to EuroQol EQ-5D health state utilities. Gu NY; Botteman MF; Ji X; Bell CF; Carter JA; van Hout B Health Qual Life Outcomes; 2011 Dec; 9():119. PubMed ID: 22208861 [TBL] [Abstract][Full Text] [Related]
5. Estimating the burden of disease in chronic pain with and without neuropathic characteristics: does the choice between the EQ-5D and SF-6D matter? Torrance N; Lawson KD; Afolabi E; Bennett MI; Serpell MG; Dunn KM; Smith BH Pain; 2014 Oct; 155(10):1996-2004. PubMed ID: 25020004 [TBL] [Abstract][Full Text] [Related]
6. Mapping between the Roland Morris Questionnaire and generic preference-based measures. Khan KA; Madan J; Petrou S; Lamb SE Value Health; 2014 Sep; 17(6):686-95. PubMed ID: 25236992 [TBL] [Abstract][Full Text] [Related]
7. Probabilistic mapping of descriptive health status responses onto health state utilities using Bayesian networks: an empirical analysis converting SF-12 into EQ-5D utility index in a national US sample. Le QA; Doctor JN Med Care; 2011 May; 49(5):451-60. PubMed ID: 21422961 [TBL] [Abstract][Full Text] [Related]
8. Converting Parkinson-Specific Scores into Health State Utilities to Assess Cost-Utility Analysis. Chen G; Garcia-Gordillo MA; Collado-Mateo D; Del Pozo-Cruz B; Adsuar JC; Cordero-Ferrera JM; Abellán-Perpiñán JM; Sánchez-Martínez FI Patient; 2018 Dec; 11(6):665-675. PubMed ID: 29876865 [TBL] [Abstract][Full Text] [Related]
9. Estimating the relationship between preference-based generic utility instruments and disease-specific quality-of-life measures in severe chronic constipation: challenges in practice. Parker M; Haycox A; Graves J Pharmacoeconomics; 2011 Aug; 29(8):719-30. PubMed ID: 21635017 [TBL] [Abstract][Full Text] [Related]
10. Longitudinal predictive ability of mapping models: examining post-intervention EQ-5D utilities derived from baseline MHAQ data in rheumatoid arthritis patients. Kontodimopoulos N; Bozios P; Yfantopoulos J; Niakas D Eur J Health Econ; 2013 Apr; 14(2):307-14. PubMed ID: 22252308 [TBL] [Abstract][Full Text] [Related]
11. Mapping analyses to estimate EQ-5D utilities and responses based on Oxford Knee Score. Dakin H; Gray A; Murray D Qual Life Res; 2013 Apr; 22(3):683-94. PubMed ID: 22555470 [TBL] [Abstract][Full Text] [Related]
12. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D. Hawton A; Green C; Telford C; Zajicek J; Wright D Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811 [TBL] [Abstract][Full Text] [Related]
13. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments. Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372 [TBL] [Abstract][Full Text] [Related]
14. Mapping the COPD Assessment Test onto EQ-5D. Hoyle CK; Tabberer M; Brooks J Value Health; 2016 Jun; 19(4):469-77. PubMed ID: 27325339 [TBL] [Abstract][Full Text] [Related]
15. Mapping health-related quality of life scores from FACT-G, FAACT, and FACIT-F onto preference-based EQ-5D-5L utilities in non-small cell lung cancer cachexia. Meregaglia M; Borsoi L; Cairns J; Tarricone R Eur J Health Econ; 2019 Mar; 20(2):181-193. PubMed ID: 28948436 [TBL] [Abstract][Full Text] [Related]
16. A mapping study in mainland China: predicting EQ-5D-5L utility scores from the psoriasis disability index. Su J; Liu T; Li S; Zhao Y; Kuang Y J Med Econ; 2020 Jul; 23(7):737-743. PubMed ID: 32223358 [No Abstract] [Full Text] [Related]
17. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model. Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011 [TBL] [Abstract][Full Text] [Related]
18. Mapping CushingQOL scores to EQ-5D utility values using data from the European Registry on Cushing's syndrome (ERCUSYN). Badia X; Roset M; Valassi E; Franz H; Forsythe A; Webb SM Qual Life Res; 2013 Dec; 22(10):2941-50. PubMed ID: 23539468 [TBL] [Abstract][Full Text] [Related]
19. Mapping the modified Rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome. Rivero-Arias O; Ouellet M; Gray A; Wolstenholme J; Rothwell PM; Luengo-Fernandez R Med Decis Making; 2010; 30(3):341-54. PubMed ID: 19858500 [TBL] [Abstract][Full Text] [Related]
20. Mapping AcroQoL scores to EQ-5D to obtain utility values for patients with acromegaly. Badia X; Trainer P; Biermasz NR; Tiemensma J; Carreño A; Roset M; Forsythe A; Webb SM J Med Econ; 2018 Apr; 21(4):382-389. PubMed ID: 29261359 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]